Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjuvant therapy of gastrointestinal stromal tumors (GIST).

Current treatment options in oncology - 1 Sept 2012

Casali Paolo G, Fumagalli Elena, Gronchi Alessandro

Abstract excerpt

Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). Currently, there is proof that it is able to delay relapse and prolong survival. An effect on cure rate of localized GIST is still to be proven, given the shape of relapse-free survival curves, which apparently tend to overlap after 2-3 years from completion of the adjuvant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Chemotherapy, Adjuvant
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 22743760
DOI: 10.1007/s11864-012-0198-0

Genes

PDGFRA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjuvant therapy of gastrointestinal stromal tumors (GIST).PMID 22743760Read ↗

Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.Semantic proximity Read ↗

Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective studySemantic proximity Read ↗

Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.Semantic proximity Read ↗

Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in ChinaSemantic proximity Read ↗

Imatinib treatment for gastrointestinal stromal tumour (GIST).Semantic proximity Read ↗

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.Semantic proximity Read ↗

[Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].Semantic proximity Read ↗

[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].Semantic proximity Read ↗

Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.Semantic proximity Read ↗

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.Semantic proximity Read ↗

Perioperative treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Next questions for the medical treatment of gastrointestinal stromal tumor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.